Drug treatment of chronic heart failure with reduced ejection fraction (HFrEF) is well established, with a wealth of supporting evidence from clinical trials. ACE inhibitors or ARBs, beta blockers, and loop diuretics are typically used in the first-line treatment of HFrEF patients. Given the heavily genericized nature of the market, branded agents, such as Novartis’s Entresto, Amgen’s Corlanor, AstraZeneca’s Farxiga, and Eli Lilly’s Jardiance, have had difficulty establishing a foothold; nevertheless, use of Entresto has grown steadily since its launch in 2015. This analysis offers insight into the U.S. prescribing patterns in the HFrEF subpopulation.
Questions answered
Product dscription
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Pfizer, Merck, Novartis, GSK, AstraZeneca, Johnson & Johnson, Eli Lilly, Boehringer Ingelheim, Amgen
Key drugs: ACE inhibitors, ARBs, beta blockers, diuretics, aldosterone antagonists, nitrates, Entresto, Corlanor, Farxiga, Jardiance, Verquvo
Solution enhancement
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.